A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use

Journal of Immunological Methods

Volumn 245, Issue 1-2, 2000, Pages 15-29

  Feuerstein, Bernadette ^a   Berger, Thomas G ^a   Maczek, Christian ^a   Röder, Claudia ^a   Schreiner, Doris ^a   Hirsch, Ute ^a   Haendle, Ina ^a   Leisgang, Waltraud ^a   Glaser, Anke ^a   Kuss, Oliver ^b   Diepgen, Thomas L ^b   Schuler, Gerold ^a   Schuler Thurner, Beatrice ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cryopreservation; Dendritic cells; Immunotherapy

Indexed keywords

ANTIGEN; GLYCOPROTEIN GP 39; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; MATRIX PROTEIN; MELAN A PEPTIDE; PROSTAGLANDIN E2; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIGEN;

ARTICLE; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; CRYOPRESERVATION; DENDRITIC CELL; HUMAN; HUMAN CELL; LEUKAPHERESIS; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; VACCINATION;

ANTIGENS; CARRIER PROTEINS; CD40 LIGAND; CELL DIFFERENTIATION; CELL SURVIVAL; CRYOPRESERVATION; DENDRITIC CELLS; HUMAN; IMMUNOTHERAPY; IN VITRO; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE GLYCOPROTEINS; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; TETANUS TOXOID; VACCINES;

EID: 0034332994     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00269-6     Document Type: Article

References (34)

1. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
2. Dendritic cells and the control of immunity
3. Dendritic cells
4. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
5. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+T cells
6. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
7. Activation of human dendritic cells through CD40 cross-linking
8. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
9. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes
10. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
11. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
12. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
13. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
14. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
15. Proper statistical analysis of transepidermal water loss (TEWL) measurements in bioengineering studies
16. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
17. A cryopreservation method of human peripheral blood mononuclear cells for efficient production of dendritic cells
18. Incorporation of an Isoleucin Zipper Motif enhances the biological activity of soluble CD40L (CD154)
19. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
20. Prostaglandin E2 and tumor necrosis factor a cooperate to activate human dendritic cells: Synergistic activation of interleukin 12 production
21. Proliferating dendritic cell progenitors in human blood
22. Generation of mature dendritic cells from human blood - An improved method with special regard to clinical applicability
23. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
24. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-alpha
25. Dendritic cells as adjuvants for immune-mediated resistance to tumors
26. + blood progenitors for anticancer therapy
27. GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial
28. The cryobiology of rat and human dendritic cells: Preservation and destruction of membrane integrity by freezing
29. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
30. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
31. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
32. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent
33. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor